A phase II trial of naxitamab plus stepped‐up dosing of GM ‐ CSF for patients with high‐risk neuroblastoma in second or later complete remission

Documenti analoghi

• Naxitamab with novel scheduling and stepped‐up dosing of GM ‐ CSF plus vaccine, but no myeloablative therapy for patients with high‐risk neuroblastoma in first complete remission
  di: Brian H. Kushner, et al.
  Pubblicazione: (2026)
• Rapid COJEC without myeloablative therapy for high‐risk neuroblastoma
  di: Brian H. Kushner, et al.
  Pubblicazione: (2025)
• Pulmonary Toxicity Associated With Concurrent Lorlatinib and Anti‐GD2 Monoclonal Antibody Therapy in Patients With Neuroblastoma
  di: Wei Wei, et al.
  Pubblicazione: (2025)
• Pulmonary hypertension during high‐dose GM‐CSF therapy of autoimmune pulmonary alveolar proteinosis
  di: Ali Ataya, et al.
  Pubblicazione: (2024)
• A Single Institutional Experience Using Romiplostim to Treat Therapy‐Related Thrombocytopenia in Pediatric Solid Tumor Patients
  di: Melanie D. Degliuomini, et al.
  Pubblicazione: (2025)